Sana Biotechnology, Inc.

SANA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.27 0.21 −8.47%
Market cap
$740.9M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
1.38 1.29 1.89 4.55

+8 more quarters

Net Debt/EBITDA
2.61 2.28 2.45 3.90
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.12) (0.14) (0.13) (0.11)
Book value per Share
0.52 0.43 0.64 0.75
Free Cash Flow
(34.39) (37.42) (32.85) (29.33)
Other line items

Show all line items

Columns are period end dates